Trials / Unknown
UnknownNCT03126071
Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
A Phase II Study of Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Jiangsu Cancer Institute & Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Raltitrexed | Raltitrexed:3mg/m2,iv 15min,d1,q3w. |
| DRUG | Irinotecan | Irinotecan:250mg/m2,iv 90min,d1,q3w. |
| DRUG | Oxaliplatin | Oxaliplatin:130mg/m2,iv 120min,d1,q3w. |
| DRUG | Bevacizumab | Bevacizumab:75mg/kg,iv 30min,d1,q3w. |
Timeline
- Start date
- 2017-02-15
- Primary completion
- 2022-08-15
- Completion
- 2023-02-15
- First posted
- 2017-04-24
- Last updated
- 2021-08-30
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03126071. Inclusion in this directory is not an endorsement.